NCT03685591 2024-06-26PF-06952229 Treatment in Adult Patients With Advanced Solid TumorsPfizerPhase 1 Terminated49 enrolled 33 charts
NCT02164461 2024-05-20Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical CancerAdvaxis, Inc.Phase 1 Completed12 enrolled 18 charts
NCT00542308 2023-08-03Zalutumumab in Non-curable Patients With SCCHNGenmabPhase 2 Completed90 enrolled 10 charts
NCT03989115 2023-06-26Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCRevolution Medicines, Inc.Phase 1/2 Completed113 enrolled 22 charts
NCT01234480 2023-05-16Intended Use Study of the BD SurePath Plusâ„¢ PapBecton, Dickinson and CompanyTerminated5,859 enrolled 4 charts
NCT00705016 2014-04-30ADVANTAGEMerck KGaA, Darmstadt, GermanyPhase 1/2 Completed184 enrolled 20 charts
NCT00382031 2013-10-15Zalutumumab in Patients With Non-curable Head and Neck CancerGenmabPhase 3 Completed286 enrolled 12 charts
NCT00401401 2011-12-23Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck CancerGenmabPhase 1/2 Terminated30 enrolled 13 charts
NCT00229723 2009-08-04IRESSAâ„¢ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell CarcinomaAstraZenecaPhase 2 Completed224 enrolled 21 charts